This report was first published by Endpoints News. To see the original version, click here
Icon said it is continuing to face project cancellations as customers are decreasing their early research spending. As for Medpace, the company said the worst might be over.
Icon on Wednesday said it is still facing challenges with customers canceling projects or delaying their decision-making. At the beginning of the year, President Donald Trump made sweeping NIH funding cuts, causing companies to pull back on R&D spending with CROs.
您已閱讀26%（527字），剩余74%（1529字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。